Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Found to Fight Marfan (Australia)

This article was originally published in PharmAsia News

Executive Summary

Researchers at the Baker Heart Research Institute in Melbourne, Australia, have discovered an existing drug that may be helpful for treating Marfan syndrome. The drug, called perindopril, works to reduce the fragility of the aorta. Aortic rupture is the leading cause of death in people with Marfan, which is a genetic condition that causes imperfections in the connective tissues of the body's skeletal, ocular, and cardiovascular systems. Up until now, most patients with Marfan had to take beta-blockers to slow their heart rate in an attempt to prevent stress on the aorta. But these drugs do nothing to strengthen the aorta and Marfan sufferers often have to undergo multiple heart surgeries, which are both expensive and risky. Scientists say using perindopril will cut down on the need for those surgeries, increasing the quality of life for those with the disease. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel